RxDoctor Payments Data

Alyssa Degnan, DO

Internal Medicine · Aiken, SCNPI 1447243654

Payments from drug & device makers

$347in general payments, 2019–2025

Across 24 payments — averaging $14.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$85
  • Takeda Pharmaceuticals U.S.A., Inc.$54
  • Amgen$43
  • AbbVie$29
  • Johnson & Johnson$26
  • AstraZeneca$21
  • plus $89 from 6 others

What the payments were for

  • Food & beverage$33396%
  • Education$144%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$347 in reported general payments places this provider in the 50th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$278,931
Medicare patients
418
Services billed
5,265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban138$131,736
JardianceEmpagliflozin98$85,997
MounjaroTirzepatide53$64,394
OzempicSemaglutide39$47,498
JanuviaSitagliptin Phosphate27$29,011
MyrbetriqMirabegron48$26,807
EntrestoSacubitril/Valsartan28$26,790
RybelsusSemaglutide17$20,016
XareltoRivaroxaban12$18,360
Tresiba Flextouch U-100Insulin Degludec17$14,810
Breo ElliptaFluticasone/Vilanterol14$14,760
TrulicityDulaglutide11$10,488
EdarbyclorAzilsartan Med/Chlorthalidone31$10,130
Desvenlafaxine Succinate ErDesvenlafaxine Succinate113$9,248
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$15$133,165186 claims
Novo NordiskOzempic, Rybelsus$85$67,51456 claims
NovartisEntresto$15$26,79028 claims
Johnson & JohnsonXarelto$26$18,36012 claims
Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi$14$17,10847 claims
AbbVieSynthroid$29$2,97050 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Aiken

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →